



## Great Basin Scientific to Demonstrate its Diagnostics Platform at AMP 2016

*Featured poster demonstrates expanded clinical utility of the Company's Group B Streptococcus (GBS) assay*

**Salt Lake City, November 10, 2016** – Great Basin Scientific, Inc. (OTCQB: GBSN), a molecular diagnostics company, will demonstrate its molecular diagnostics platform at the Association for Molecular Pathology (AMP) 2016 Annual Meeting in Charlotte, North Carolina, November 10-12. At booth 302, the Company will show conference attendees the ease-of-use and simple workflow of its sample-to-result system, designed to help small to medium-sized hospitals reduce costs and provide better patient outcomes.

In addition to the exhibition, Great Basin Scientific's technology will be presented with clinical study findings in a poster titled "*Implementation of the Great Basin Group B Streptococcus (GBS) Assay using Hardy Carrot Broth in a Community Hospital Laboratory,*" selected to be presented within the Infectious Diseases category. The study findings demonstrate the feasibility of carrot broth testing on the Great Basin system, a sample type not included in Great Basin's GBS clinical trial. The demonstrated feasibility of carrot broth as a specimen culture media potentially expands the utility and market opportunity of the Company's GBS test at hospitals and labs using carrot broth enrichment for patient samples.

The presenting author will be available during the poster session in the Exhibit Hall on Friday, November 11, 2:30pm – 3:30pm ET. Further, the poster will be available for download from the Great Basin website after the close of the Annual Meeting.

### **About AMP**

The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,300+ members practice in the various disciplines of molecular diagnostics, including infectious diseases, inherited conditions and oncology. They include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international



levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit [www.amp.org](http://www.amp.org) and follow us on Twitter at [@AMPath](https://twitter.com/AMPath).

### **About Great Basin Scientific**

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at [www.gbscience.com](http://www.gbscience.com).

### **Forward-Looking Statements**

This press release includes forward-looking statements regarding the Company's continuing business efforts related to its products, including but not limited to, presentation at the AMP, the demonstrated feasibility of carrot broth as a specimen culture media potentially expands the utility and market opportunity for the Company's GBS test and expansion of the Company's menu. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

### **Media Contact:**

Nirav Suchak

ICR



646.277.1257

[nirav.suchak@icrinc.com](mailto:nirav.suchak@icrinc.com)

**Investor Relations Contact:**

Betsy Hartman

Great Basin Scientific

385.215.3372

[ir@gbscience.com](mailto:ir@gbscience.com)

###